ESMO Immuno-Oncology 2022 | Optimizing TILs as a novel immunotherapy strategy in metastatic melanoma

Results from a Phase III trial (NCT02278887) evaluating a tumor infiltrating lymphocyte (TIL) in metastatic melanoma have demonstrated this form of immunotherapy as a promising therapeutic option in this field. Maartje Rohaan, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, describes strategies to enhance TILs. Whilst the standard manufacturing methods were used in the trial, elucidating alternative strategies that can shorten production time as well as reduce adverse effects will benefit patients in the long term. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.